This is an old revision of the document!

Drug Name
Brand Names	Brand1®, Brand2®
Drug Class	Class Name
Subclass	Subclass
Primary Indications	Indication 1; Indication 2
Route(s)	Oral / IV / SQ / INH
Onset
Duration
Metabolism	CYP ___ / none
Half-life
Elimination	Renal / Hepatic / Both
Pregnancy
Renal Adjustment	Yes / No
Hepatic Adjustment	Yes / No
Black Box Warning	Yes / No
Controlled	No / C-II / C-IV
FDA Approval	YYYY

Generic (Brand®)

Endocrine Common First-line <!– Optional badges –> <!– Black Box –> <!– QT Risk –>

<button data-expandall>Expand All</button> <button data-collapseall>Collapse All</button>

Overview

One tight paragraph:

What the drug is
Where it fits clinically (first-line vs add-on)
The “why it matters” outcome or key role

Mechanism of Action

Primary target (receptor/enzyme/transporter):
Downstream signal/pathway:
Net physiologic effect (what variable changes):
Why that helps the disease state:

Indications

Black Box Warning

(If none, delete this entire blackbox section.)

Contraindications

Absolute:

Relative / Cautions:

Dosing

Adult:

Starting dose:
Typical dose:
Max dose:

Titration:

Renal dosing:

Hepatic dosing:

Special populations:

Elderly:
Pregnancy:

Pharmacokinetics

Absorption:

Bioavailability:

Protein binding:

Distribution:

Metabolism:

CYP pathways: (if relevant)

Half-life:

Elimination:

Renal / Hepatic / Both

Adverse Effects

Common:

Serious:

Mechanism-based:

Drug Interactions

CYP:

Inhibitors:
Inducers:

Additive physiologic effects:

High-yield “do not miss”:

Monitoring

Vitals:

Labs:

ECG (if relevant):

Clinical response:

Clinical Pearls

Comparison Within Class

How it differs from others in Class Name:
- potency / selectivity:
- duration:
- renal vs hepatic clearance:
- outcome evidence:
- “best use case” patient: